Extracellular vesicles as biomarkers of systemic lupus erythematosus

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Perez Hernandez, Javier ^a   Cortes, Raquel ^a  

^a Instituto Universitario IVI INCLIVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; BIOLOGICAL MARKER; CYTOKINE;

BIOGENESIS; DISEASE ACTIVITY; DISEASE COURSE; EXOSOME; HUMAN; INFLAMMATORY DISEASE; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; METABOLISM; PATHOLOGY; URINE;

BIOMARKERS; EXTRACELLULAR VESICLES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84942278906     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/613536     Document Type: Review

References (79)

1. H. A. Al-Shobaili, A. A. Al Robaee, A. A. Alzolibani, and Z. Rasheed, "Antibodies against 4-hydroxy-2-nonenal modified epitopes recognized chromatin and its oxidized forms: role of chromatin, oxidized forms of chromatin and 4-hydroxy-2-nonenal modified epitopes in the etiopathogenesis of SLE," Disease Markers, vol. 33, no. 1, pp. 19-34, 2012.
2. T. Colasanti, A. Maselli, F. Conti et al., "Autoantibodies to estrogen receptor α interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus," Arthritis & Rheumatism, vol. 64,no. 3, pp. 778-787, 2012.
3. G. C. Tsokos, "Systemic lupus erythematosus,"TheNew England Journal of Medicine, vol. 365, no. 22, pp. 2110-2121, 2011.
4. T. Li, G. S. Carls, P. Panopalis, S. Wang, T. B. Gibson, and R. Z. Goetzel, "Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a fiveyear analysis of a large medicaid population," Arthritis Care & Research, vol. 61, no. 6, pp. 755-763, 2009.
5. K. L. Moser, J. A. Kelly, C. J. Lessard, and J. B. Harley, "Recent insights into the genetic basis of systemic lupus erythematosus," Genes and Immunity, vol. 10, no. 5, pp. 373-379, 2009.
6. S. Alfadhli, "Influence of endothelial nitric oxide synthase gene intron-4 27bp repeat polymorphism on its expression in autoimmune diseases," Disease Markers, vol. 34, no. 5, pp. 349-356, 2013.
7. Q. Lu, A.Wu, and B. C. Richardson, "Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs," The Journal of Immunology, vol. 174, no. 10, pp. 6212-6219, 2005.
8. Q. Lu, A.Wu, L. Tesmer, D. Ray, N. Yousif, and B. Richardson, "Demethylation of CD40LG on the inactive X in T cells from women with lupus,"The Journal of Immunology, vol. 179, no. 9, pp. 6352-6358, 2007.
9. N. Hu, X. Qiu, Y. Luo et al., "Abnormal histone modification patterns in lupus CD4+ T cells," The Journal of Rheumatology, vol. 35, no. 5, pp. 804-810, 2008.
10. T. Rauen, C. M. Hedrich, Y.-T. Juang, K. Tenbrock, and G. C. Tsokos, "cAMP-responsive element modulator (CREM)α protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus," The Journal of Biological Chemistry, vol. 286, no. 50, pp. 43437-43446, 2011.
11. Y. Dai, Y.-S. Huang, M. Tang et al., "Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients," Lupus, vol. 16, no. 12, pp. 939-946, 2007.
12. Y. Tang, X. Luo, H. Cui et al., "MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins," Arthritis & Rheumatism, vol. 60, no. 4, pp. 1065-1075, 2009.
13. C.M.Hedrich, T. Rauen, S. A. Apostolidis et al., "Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling," Proceedings of the National Academy of Sciences of theUnited States ofAmerica, vol. 111, no. 37, pp. 13457-13462, 2014.
14. A. Jonsen, A. Bengtsson,O.Nived, L.Truedsson, andG. Sturfelt, "Gene-environment interactions in the aetiology of systemic lupus erythematosus," Autoimmunity, vol. 40,no. 8, pp. 613-617, 2007.
15. J. Cameron and J. Stewart, "Lupus nephritis," Journal of the American Society of Nephrology, vol. 10, no. 2, pp. 413-424, 1999.
16. A. Gigante, M. L. Gasperini, A. Afeltra et al., "Cytokines expression in SLE nephritis," European Review for Medical and Pharmacological Sciences, vol. 15, no. 1, pp. 15-24, 2011.
17. L. M. Ortega, D. R. Schultz, O. Lenz, V. Pardo, and G. N. Contreras, "Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions," Lupus, vol. 19, no. 5, pp. 557-574, 2010.
18. G. S.Hill, M. Delahousse, D.Nochy, C.Mandet, and J. Bariety, "Proteinuria and tubulointerstitial lesions in lupus nephritis," Kidney International, vol. 60, no. 5, pp. 1893-1903, 2001.
19. A. Zickert, B. Sundelin, E. Svenungsson, and I. Gunnarsson, "Role of early repeated renal biopsies in lupus nephritis," Lupus Science & Medicine, vol. 1, Article ID e000018, 2014.
20. D. D. Gladman, D. Ibanez, and M. B. Urowltz, "Systemic lupus erythematosus disease activity index 2000," The Journal of Rheumatology, vol. 29, no. 2, pp. 288-291, 2002.
21. C. Lasser, V. Seyed Alikhani, K. Ekstrom et al., "Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages," Journal of Translational Medicine, vol. 9, article 9, 2011.
22. E. Lazaro-Ibanez, A. Sanz-Garcia, T. Visakorpi et al., "Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes," The Prostate, vol. 74, no. 14, pp. 1379-1390, 2014.
23. M. Yanez-Mo, P. R.-M. Siljander, Z. Andreu et al., "Biological properties of extracellular vesicles and their physiological functions," Journal of Extracellular Vesicles, vol. 4, Article ID27066, 2015.
24. S. A. Bellingham, B. M. Coleman, and A. F. Hill, "Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells," Nucleic Acids Research, vol. 40, no. 21, pp. 10937-10949, 2012.
25. H. Valadi, K. Ekstrom, A. Bossios, M. Sjostrand, J. J. Lee, and J. O. Lotvall, "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells," Nature Cell Biology, vol. 9, no. 6, pp. 654-659, 2007.
26. E.Cocucci,G. Racchetti, and J.Meldolesi, "Shedding microvesicles: artefacts no more," Trends in Cell Biology, vol. 19, no. 2, pp. 43-51, 2009.
27. S. Mathivanan, J. W. E. Lim, B. J. Tauro, H. Ji, R. L. Moritz, and R. J. Simpson, "Proteomics analysis of A33 immunoaffinitypurified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature," Molecular & Cellular Proteomics, vol. 9, no. 2, pp. 197-208, 2010.
28. J. Kowal, M. Tkach, and C. Thery, "Biogenesis and secretion of exosomes," Current Opinion in Cell Biology, vol. 29, no. 1, pp. 116-125, 2014.
29. J. C. Akers, D. Gonda, R. Kim, B. S. Carter, and C. C. Chen, "Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies," Journal of Neuro-Oncology, vol. 113, no. 1, pp. 1-11, 2013.
30. J. Lotvall, A. F. Hill, F. Hochberg et al., "Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles," Journal of Extracellular Vesicles, vol. 3, Article ID 26913, 2014.
31. C.Thry, S. Amigorena, G. Raposo, and A. Clayton, "UNIT 3.22 Isolation and characterization of exosomes from cell culture supernatants and biological fluids," in Current Protocols in Cell Biology, pp. 22-29, JohnWiley & Sons, 2006.
32. A. Cheruvanky, H. Zhou, T. Pisitkun et al., "Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator," The American Journal of Physiology-Renal Physiology, vol. 292, no. 5, pp. F1657-F1661, 2007.
33. D. Wang and W. Sun, "Urinary extracellular microvesicles: isolation methods and prospects for urinary proteome," Proteomics, vol. 14, no. 16, pp. 1922-1932, 2014.
34. J. Schageman, E. Zeringer, M. Li et al., "The complete exosome workflow solution: from isolation to characterization of RNA cargo," BioMed Research International, vol. 2013, Article ID 253957, 15 pages, 2013.
35. L. Muller, C.-S. Hong, D. B. Stolz, S. C. Watkins, and T. L. Whiteside, "Isolation of biologically-active exosomes from human plasma," Journal of ImmunologicalMethods, vol. 411, pp. 55-65, 2014.
36. H.Kalra, R. J. Simpson, H. Ji et al., "Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation," PLoS Biology, vol. 10, no. 12, Article ID e1001450, 2012.
37. R. J. Simpson, H. Kalra, and S. Mathivanan, "ExoCarta as a resource for exosomal research," Journal of Extracellular Vesicles, vol. 1, 2012.
38. D.-K. Kim, J. Lee, S. R. Kim et al., "EVpedia: a community web portal for extracellular vesicles research," Bioinformatics, vol. 31, no. 6, pp. 933-939, 2015.
39. H. Huang, J. Evankovich, W. Yan et al., "Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice," Hepatology, vol. 54, no. 3, pp. 999-1008, 2011.
40. F. G. Goh and K. S. Midwood, "Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis," Rheumatology, vol. 51, no. 1,Article ID ker257, pp. 7-23, 2012.
41. M. Schiller, P. Heyder, S. Ziegler et al., "During apoptosis HMGB1 is translocated into apoptotic cell-derived membraneous vesicles," Autoimmunity, vol. 46, no. 5, pp. 342-346, 2013.
42. E. Boilard, P. A. Nigrovic, K. Larabee et al., "Platelets amplify inflammation in arthritis via collagen-dependent microparticle production," Science, vol. 327, no. 5965, pp. 580-583, 2010.
43. L. A. Truman, C. A. Ford, M. Pasikowska et al., "CX3CL 1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis," Blood, vol. 112, no. 13, pp. 5026-5036, 2008.
44. N. Cloutier, S. Tan, L. H. Boudreau et al., "The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes," EMBO Molecular Medicine, vol. 5, no. 2, pp. 235-249, 2013.
45. A. J. Ullal and D. S. Pisetsky, "The role of microparticles in the generation of immune complexes in murine lupus," Clinical Immunology, vol. 146, no. 1, pp. 1-9, 2013.
46. N. Mor-Vaknin, F. Kappes, A. E. Dick et al., "DEK in the synovium of patients with juvenile idiopathic arthritis: characterization ofDEKantibodies and posttranslationalmodification of the DEK autoantigen," Arthritis & Rheumatism, vol. 63, no. 2, pp. 556-567, 2011.
47. L. E. Munoz, C. Janko, G. E. Grossmayer et al., "Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus," Arthritis and Rheumatism, vol. 60, no. 6, pp. 1733-1742, 2009.
48. J. Dieker, L. Hilbrands, A. Thielen, H. Dijkman, J. H. Berden, and J. van der Vlag, "Enhanced activation of dendritic cells by autologous apoptotic microvesicles in MRL/lpr mice," Arthritis Research & Therapy, vol. 17, article 103, 2015.
49. C. T. Nielsen, O. Øtergaard, C. Johnsen, S. Jacobsen, and N. H. H. Heegaard, "Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus," Arthritis & Rheumatism, vol. 63, no. 10, pp. 3067-3077, 2011.
50. O. Øtergaard, C. T. Nielsen, L. V. Iversen et al., "Unique protein signature of circulating microparticles in systemic lupus erythematosus," Arthritis & Rheumatism, vol. 65, no. 10, pp. 2680-2690, 2013.
51. J. R. Dye, A. J. Ullal, and D. S. Pisetsky, "The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus," Scandinavian Journal of Immunology, vol. 78, no. 2, pp. 140-148, 2013.
52. E. K. Kapsogeorgou, R. F. Abu-Helu, H. M. Moutsopoulos, and M. N. Manoussakis, "Salivary gland epithelial cell exosomes: a source of autoantigenic ribonucleoproteins," Arthritis & Rheumatism, vol. 52, no. 5, pp. 1517-1521, 2005.
53. B. Parker, A. Al-Husain, P. Pemberton et al., "Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus," Annals of the Rheumatic Diseases, vol. 73, no. 6, pp. 1144-1150, 2014.
54. T. Pisitkun, R.-F. Shen, and M. A. Knepper, "Identification and proteomic profiling of exosomes in human urine," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 36, pp. 13368-13373, 2004.
55. K. C. Miranda, D. T. Bond, M. McKee et al., "Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease," Kidney International, vol. 78,no. 2, pp. 191-199, 2010.
56. F. Barutta, M. Tricarico, A. Corbelli et al., "Urinary exosomal microRNAs in incipient diabetic nephropathy," PLoS ONE, vol. 8, no. 11, Article ID e73798, 2013.
57. H. Zhou, A. Cheruvanky, X. Hu et al., "Urinary exosomal transcription factors, a new class of biomarkers for renal disease," Kidney International, vol. 74, no. 5, pp. 613-621, 2008.
58. S. Bala, J. Petrasek, S. Mundkur et al., "Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases," Hepatology, vol. 56, no. 5, pp. 1946-1957, 2012.
59. L. Cheng, X. Sun, B. J. Scicluna, B. M. Coleman, and A. F. Hill, "Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine," Kidney International, vol. 86, no. 2, pp. 433-444, 2014.
60. O. Ichii, S. Otsuka-Kanazawa, T. Horino et al., "Decreased miR-26a expression correlates with the progression of podocyte injury in autoimmune glomerulonephritis," PLoS ONE, vol. 9, no. 10,Article ID e110383, 2014.
61. C. Sole, J. Cortes-Hernandez, M. L. Felip, M. Vidal, and J. Ordi-Ros, "miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis,"Nephrology Dialysis Transplantation, vol. 30, no. 9, pp. 1488-1496, 2015.
62. Y. Tang, X. Luo, H. Cui et al., "MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins," Arthritis and Rheumatism, vol. 60, no. 4, pp. 1065-1075, 2009.
63. G. Wang, L.-S. Tam, E. K.-M. Li et al., "Serum and urinary cell-freeMiR-146a andMiR-155 in patients with systemic lupus erythematosus,"The Journal of Rheumatology, vol. 37, no. 12, pp. 2516-2522, 2010.
64. H.Wang, W. Peng, X. Ouyang, W. Li, and Y. Dai, "Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus," Translational Research, vol. 160, no. 3, pp. 198-206, 2012.
65. J. Lu, B. C.-H. Kwan, F. M.-M. Lai et al., "Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis," Nephrology, vol. 17, no. 4, pp. 346-351, 2012.
66. S. E. Lofgren, J. Frostegard, L. Truedsson et al., "Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene," Genes and Immunity, vol. 13, no. 3, pp. 268-274, 2012.
67. L.-L. Lv, Y.-H. Cao,M.-M. Pan et al., "CD2APmRNA in urinary exosome as biomarker of kidney disease," Clinica Chimica Acta, vol. 428, pp. 26-31, 2014.
68. S. Spanu, C. R. C. van Roeyen, B. Denecke, J. Floege, and A. S. Muhlfeld, "Urinary exosomes: a novel means to non-invasively assess changes in renal gene and protein expression," PLoSONE, vol. 9, no. 10, Article ID e109650, 2014.
69. P.Gutwein,A. Schramme,M. S. Abdel-Bakky et al., "ADAM10 is expressed in human podocytes and found in urinary vesicles of patients with glomerular kidney diseases," Journal of Biomedical Science, vol. 17, no. 1, article 3, 2010.
70. T.Niranjan, B. Bielesz, A. Gruenwaldet al., "TheNotchpathway in podocytes plays a role in the development of glomerular disease," Nature Medicine, vol. 14, no. 3, pp. 290-298, 2008.
71. K. Al-Nedawi, B. Meehan, J. Micallef et al., "Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells," Nature Cell Biology, vol. 10, no. 5, pp. 619-624, 2008.
72. M. F. Baietti, Z. Zhang, E. Mortier et al., "Syndecan-syntenin-ALIX regulates the biogenesis of exosomes," Nature Cell Biology, vol. 14, no. 7, pp. 677-685, 2012.
73. A. Bobrie, S. Krumeich, F. Reyal et al., "Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression," Cancer Research, vol. 72, no. 19, pp. 4920-4930, 2012.
74. D. Sun, X. Zhuang, X. Xiang et al., "A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes,"MolecularTherapy, vol. 18, no. 9, pp. 1606-1614, 2010.
75. G.-J. Wang, Y. Liu, A. Qin et al., "Thymus exosomes-like particles induce regulatory T cells," The Journal of Immunology, vol. 181, no. 8, pp. 5242-5248, 2008.
76. S.-H. Kim, E. R. Lechman, N. Bianco et al., "Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis,"TheJournal of Immunology, vol. 174, no. 10, pp. 6440-6448, 2005.
77. S. H. Kim, N. Bianco, R.Menon et al., "Exosomes derived from geneticallymodifiedDC expressing FasL are anti-inflammatory and immunosuppressive," MolecularTherapy, vol. 13, no. 2, pp. 289-300, 2006.
78. L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhal, and M. J. A. Wood, "Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes," Nature Biotechnology, vol. 29, no. 4, pp. 341-345, 2011.
79. N.Cloutier, A. Pare, R.W. Farndale et al., "Platelets can enhance vascular permeability," Blood, vol. 120, no. 6, pp. 1334-1343, 2012.